OVERALL DESIGN: This study is an open-label, single-center, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, and tolerability of ES014 in adults with advanced solid tumors. Adult patients with unresectable locally advanced or metastatic solid tumors will be enrolled in this study. This study is not blinded.
Subject type and number : The study population will be adults with unresectable locally advanced or metastatic solid tumors, whose disease has progressed despite standard therapy and for whom no further standard therapy exists; or for whom standard therapy has proven to be ineffective or intolerable.
This study is expected to enroll no more than 15 subjects, including malignant pleural mesothelioma and myxofibrosarcoma, 4-5, respectively, 2-3 malignant peripheral nerve sheath tumors, and other solid tumors.
Duration of treatment: Subjects will be treated with ES014 in 28-day cycles. ES014 will be administered at 1400 mg on days 1 and 15 of each cycle. Each subject will be treated with study drug for a maximum of 24 months. Subjects will be treated according to protocol until disease progression per RECIST v1.1, development of unacceptable toxicity, withdrawal of consent, completion of study treatment of 24 months, end of study, or early termination of study by sponsor, or other discontinuation and withdrawal reason, whichever occurs first.

开始日期2024-08-20

申办/合作机构

中国医学科学院肿瘤医院

[+1]

NCT05381935 / Withdrawn临床1期

An Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion, Phase 1 Study of ES014 in Subjects With Locally Advanced or Metastatic Solid Tumors

The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES014 by evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of ES014 administered intravenously to subjects with advanced solid tumors.

开始日期2023-04-21

申办/合作机构

科望（上海）生物医药科技有限公司初创企业

NCT05717348 / Recruiting临床1期

An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES014 Administered in Patients Locally Advanced or Metastatic Solid Tumours

开始日期2023-02-21

申办/合作机构

科望（苏州）生物医药科技有限公司

100 项与 ES-014 相关的临床结果

登录后查看更多信息

100 项与 ES-014 相关的转化医学

登录后查看更多信息

100 项与 ES-014 相关的专利（医药）

登录后查看更多信息

项与 ES-014 相关的文献（医药）

2016-01-01·Animal : an international journal of animal bioscience2区 · 农林科学

Egg storage duration and hatch window affect gene expression of nutrient transporters and intestine morphological parameters of early hatched broiler chicks

2区 · 农林科学

Article

作者: Gursel, I ; Horuluoglu, B H ; Bilgen, G ; Yalcin, S ; Izzetoglu, G T ; Gucluer, G

In recent years, researchers have given emphasis on the differences in physiological parameters between early and late hatched chicks within a hatch window. Considering the importance of intestine development in newly hatched chicks, however, changes in gene expression of nutrient transporters in the jejunum of early hatched chicks within a hatch window have not been studied yet. This study was conducted to determine the effects of egg storage duration before incubation and hatch window on intestinal development and expression of PepT1 (H+-dependent peptide transporter) and SGLT1 (sodium-glucose co-transporter) genes in the jejunum of early hatched broiler chicks within a 30 h of hatch window. A total of 1218 eggs obtained from 38-week-old Ross 308 broiler breeder flocks were stored for 3 (ES3) or 14 days (ES14) and incubated at the same conditions. Eggs were checked between 475 and 480 h of incubation and 40 chicks from each egg storage duration were weighed; chick length and rectal temperature were measured. The chicks were sampled to evaluate morphological parameters and PepT1 and SGLT1 expression. The remaining chicks that hatched between 475 and 480 h were placed back in the incubator and the same measurements were conducted with those chicks at the end of hatch window at 510 h of incubation. Chick length, chick dry matter content, rectal temperature and weight of small intestine segments increased, whereas chick weight decreased during the hatch window. The increase in the jejunum length and villus width and area during the hatch window were higher for ES3 than ES14 chicks. PepT1 expression was higher for ES3 chicks compared with ES14. There was a 10.2 and 17.6-fold increase in PepT1 and SGLT1 expression of ES3 chicks at the end of hatch window, whereas it was only 2.3 and 3.3-fold, respectively, for ES14 chicks. These results suggested that egg storage duration affected development of early hatched chicks during 30 h of hatch window. It can be concluded that the ES14 chicks would be less efficiently adapted to absorption process for carbohydrates and protein than those from ES3 at the end of the hatch window.

2011-06-14·GENETICS AND MOLECULAR RESEARCH

Assessment of genetic diversity of wheat genotypes by resistance gene analog-EST markers.

Article

作者: Gurel, F ; Karakas, O ; Uncuoglu, A A

Resistance gene analog-expressed sequence tag (RGA-EST)-based markers have been used for variety discrimination and studies of genetic diversity in wheat. Our aim is to increase the competitiveness of public wheat breeding programs through intensive use of modern selection technologies, mainly marker-assisted selection. The genetic diversity of 77 wheat nucleotide binding site (NBS)-containing RGA-ESTs was assessed. Resistant and susceptible bread wheat (Triticum aestivum) genotypes were used as sources of DNA for PCR amplifications. In our previous studies, the F₂ individuals derived from the combinations PI178383 x Harmankaya99, Izgi2001 x ES14, and Sonmez2001 x Aytin98 were evaluated for yellow rust resistance at both seedling and adult stages to identify DNA markers. We have now examined the genetic variability among the resistant and susceptible Turkish wheat cultivars for yellow rust disease and the mean genetic distance between the cultivars. The highest similarity was 0.500 between Harmankaya99 and Sonmez2001. The lowest similarity was 0.286 between Aytin98, PI178383 and Aytin98, ES14. A relatively high level (49.5%) of polymorphism was observed with 77 RGA-EST primers across the six wheat genotypes, despite the fact that all of them were local cultivars from geographically close locations. RGA-EST sequences were compared by BlastX algorithms for amino acid sequences to determine the polymorphic categories among the combinations. BlastX analyses of six RGA-ESTs that gave polymorphic patterns for all combinations were NBS-LRR class RGA, NB-ARC domain containing protein, NBS-type resistance protein RGC5, NBS-LRR-S/ TPK stem rust resistance protein, and putative MLA1 proteins, while 38 RGA-EST gave a monomorphic pattern.

2010-01-01·Wei sheng yan jiu = Journal of hygiene research

[Analysis of 16S rDNA sequence of Cronobacter spp].

Article

作者: Pei, Xiaoyan ; Liu, Xiumei

OBJECTIVE:

To analyse the sequence of 16S rDNA of twenty-nine Cronobacter spp. strains isolated from food as well as two type strains.

METHODS:

Using polymerase chain reaction to obtain the sequences of 16S rDNA of all strains. The multiple cluster analysis and phylogenetic analysis of them were studied by BioNumerics software.

RESULTS:

All strains, except ATCC51329 and ES 014, were clustered with the Cronobacter spp. type strain ATCC29544. The Cronobacter spp. type strain ATCC51329 and ES 014 belonged to a different branch. From the sequence analysis of 16S rDNA, all these isolates of Cronobacter spp. except ES 014 could be identified accurately by gene analysis.

CONCLUSION:

All Cronobacter spp. strains isolated from food were identified on genetic level. The phylogenetic relationships among related Cronobacter spp. isolates were studied.

项与 ES-014 相关的新闻（医药）

2024-02-23

·科望医药

创新药的普罗米修斯之火

科望医药“深耕创新，引领世界”年会集体照2024年伊始，和远在大洋彼岸刚举办完JPM大会的旧金山一样，上海天气也格外晴朗，一扫久陷于寒冬的阴霾。与天气格外映衬得是意气风发的科望伙伴们，在1月底迎着明媚的阳光和崭新的希望，共同打造了科望“深耕创新，引领世界”年会。这是一场含“C”(C-Suite)量不到5%的充满科望特色的年会，啥意思？1第一把火：智慧之火，智慧是创造力的源泉，智慧让我们不断学习和迭代自我，探索未知世界。早期研发团队项目经理王春年带我们回顾了科望医药第一个出海澳洲的项目ES009，目前已顺利推进到了第三个剂量组。项目发挥了集体的智慧，脚踏实地地踩出原本没有的路，并且极好的磨练了团队。ES009全新的作用机理，明确的临床需求，凭借基础生物学和肿瘤免疫学的深刻理解，科望正加速推进ES009的创新研发，早日惠及全球肿瘤患者“道阻且长，行则将至！”春年总结到。2第二把火：人才之火，在科望创新的根本是“人才”，人才之火，可以燎原。科望不但在管线研发上极具创新，在人才发展上也有独到创新的培养方式。比如“斜杠计划”。孙俊说道：“这个项目不仅让我在专业领域有深度的扩展，也扩宽并培养了我跨界的专业能力。我在稳扎稳打完成自己In Vitro 药效评价工作的同时，分别在TRM (转化医学) 和InVivo (动物药效) 团队斜杠学习，使我在科学和综合能力上都有了快速的成长，也为我自己的dream job打下夯实的基础。”如今我已经完成从一名scientist 到一个研发项目的Project Leader角色的转换，除了自己的努力以外，离不开我们每一位团队导师“授人以渔”的胸怀，也离不开公司坚定的践行人才培养的理念。乾坤未定，你我皆是黑马！3第三把火：速度之火，新药研发争分夺秒，如同和病魔在竞速，快一步患者便拥有无限可能。小伙伴们都说, ES014项目的临床执行效率又刷新了公司记录，一期爬坡比原计划提早71天完成，同时在项目质量上也堪称优秀典范。临床运营项目经理苏畅分享道：“ES014是科望全球首创的靶向CD39和TGF-β的双抗药物分子，在临床前研究阶段，该药物分子已展现出显著的肿瘤抑制特征，有望成为新一代具有单药疗效的抗肿瘤免疫药物。能够尽快将潜在的优秀药物推进到临床，临床研发的效率万众瞩目，而临床执行细节取胜，需要打了鸡血一样的紧盯好每一步、把控好整个流程，前瞻性的部署下一阶段的项目推进。跨部门团队的严谨敬业、分秒必争、通力合作是成功的关键，因为大家都深知自己的使命：无数患者在等待。”4第四把火：价值之火，价值突破是我们逐梦之旅的北极星，新的格局刚刚开始，未来就在脚下。科望伙伴们拼搏的意义在于能研发出具有临床价值的突破性创新药。“前不久公司公布的与安斯泰来就BiME® 平台及候选药物和合作，成为2023年抗体类出海的最大交易总额，” 该项目早期研发负责人孙大为提到：“科望在巨噬细胞研发的多年深耕和积累，获得跨国药企认可实属必然。”BD同事朱昭桦骄傲的说到：“借力于跨国药企的雄厚实力和全球网络能够最大化我们创新药的临床价值，此次合作成功最关键的是数据为王，知己知彼，团队合作，高效执行”。昭华和大为的分享结束于他们对于未来更长远的思考和雄心，他们说：“新的格局刚刚开始，未来就在脚下”。智慧，人才，速度，价值这4把火，犹如普罗米修斯之火点燃了所有科望人，小伙伴们已迫不及待开始了对来年的期待和规划！这些由科望小伙伴们绘制的蓝图，高屋建瓴地勾勒了出公司2024年的发展策略，老板们也忍不住点赞评论！科望小伙伴们点燃的熊熊火焰犹如普罗米修斯之火，将给新药研发和人类健康带来源源不断的光明和希望！解锁更多年会热辣滚烫瞬间：这么火的公司，还招人不？上海Discovery研发部Antibody Engineering Leader 抗体工程负责人Bispecific Antibody Functional Assay Scientist 双抗功能学研究员Clinical Biomarker Leader 转化医学负责人In Vivo Scientist 体内药理研究员Clinical临床部Regulatory Affairs Manager 注册事务经理请将简历发至：Joinus@elpiscience.com

临床1期

2023-11-05

·BioSpace

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)-- Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014. Study Highlights: Title: Selective delivery of TGFβ “trap” to CD39-expressing immune and stroma cells reshapes tumor microenvironment and rejuvenates antitumor immunity Abstract Number: 453 CD39-Adenosine and TGFβ are two key immune suppressive pathways within the tumor microenvironment (TME). TGFβ, in contrast to its biphasic effects on tumor cells, acts on stromal cells and immune cells in the TME, which commonly express high levels of CD39, to promote tumor progression. CD39-targeted TGFβ “trap” is thus more likely to effectively inhibit tumor progression. Our study showed that ES014, a bifunctional antibody–ligand trap which comprises an antibody targeting CD39 fused to a TGFβ receptor II ectodomain, can inhibit TGFβ activity and lead to cancer killing in ex vivo models. A phase I clinical study is ongoing to primarily investigate the safety, tolerability, and preliminary clinical activity of ES014 in patients with advanced solid tumors. Highlights: ES014 binds and neutralizes both CD39 and TGFβ. ES014 promoted killing of tumors from NSCLC patients in ex vivo MPE model. ES014 inhibits Treg differentiation and TGFβ-induced CD39 expression on T cells. ES014 promotes T cell survival. Title: ES015-2, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response Abstract Number: 498 The inhibitory receptor NKG2A and the activating receptor NKG2C modulate the function of NK and CD8 T cells by recognizing the same ligand HLA-E. NKG2A is selectively expressed on lymphocytes with cytolytic function, and the NKG2C “engager” has the potential to generate a strong antitumor response against various tumors. Inhibiting NKG2A and HLA-E alone was not as effective as had been expected in both mouse tumor models and in clinical trials. Our NKG2A/NKG2C dual targeting antibody ES015-2 can inhibit NKG2A function yet promoting NKG2C action, leading to superior anti-tumor response. Highlights: ES015-2 is a NKG2A/NKG2C dual targeting antibody. ES015-2 can completely block the interaction of NKG2A/CD94 with HLA-E, thereby inhibits HLA-E-induced NKG2A inhibitory signaling. Ligation of ES015-2 effectively potentiates the activation of NKG2C+ NK cells and T cells. Title: ES008-a, a high affinity LILRB1 specific blocking antibody activates multiple immune cells to fight cancers Abstract Number: 510 LILRB1 is the most broadly expressed member of LILRB family on various immune cells. Blocking LILRB1 augments macrophage phagocytosis of tumor cells, restores cytotoxic function of NK cells, and enhances tumor cell killing by effector CD8+ T cells. The high affinity LILRB1 specific blocking antibody ES008-a can activate multiple immune cells to fight cancers. Highlights: ES008-a is a high affinity LILRB1-specific blocker that can completely block HLA-G/LILRB1 and HLA-A2/LILRB1 interactions. ES008-a promotes NK cell-mediated destruction of tumor cells. ES008-a synergizes with CD47/SIRPα inhibitors in enhancing macrophage phagocytosis of tumor cells. About Elpiscience Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms. For more information, please visit: View source version on businesswire.com: Contacts BD inquiries: BD@elpiscience.com Media inquiries: PR@elpiscience.com Source: Elpiscience Biopharmaceuticals, Inc. View this news release online at:

免疫疗法临床1期AACR会议临床结果

2023-10-24

·BioSpace

Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

SHANGHAI & SUZHOU, China & GERMANTOWN, Md.--(BUSINESS WIRE)-- Elpiscience Biopharma, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego. The posters will highlight its studies on three innovative molecules including a first-in-class NKG2A/NKG2C dual-targeting antibody ES015, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014 which has been proven to be able to deliver TGFβ “trap” to CD39-expressing immune and stroma cells to reshape tumor microenvironment and rejuvenates antitumor immunity. Poster presentation details: Title: Selective delivery of TGFβ “trap” to CD39-expressing immune and stroma cells reshapes tumor microenvironment and rejuvenates antitumor immunity Abstract Number: 453 Date and time: November 3, 2023; 9 am –7 pm PDT Location: Exhibit Halls A and B1 – San Diego Convention Center Title: ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response Abstract Number: 498 Date and time: November 4, 2023; 9 am –8:30 pm PDT Location: Exhibit Halls A and B1 – San Diego Convention Center Title: ES008-a, a high affinity LILRB1 specific blocking antibody activates multiple immune cells to fight cancers Abstract Number: 510 Date and time: November 4, 2023; 9 am –8:30 pm PDT Location: Exhibit Halls A and B1 – San Diego Convention Center About Elpiscience Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. A pipeline of novel molecules has been developed using its proprietary platforms including a powerful Bispecific Macrophage Engager (BiME®) technology that connects and activates macrophages for solid tumor killing without causing cytokine storms. For more information, please visit:

免疫疗法AACR会议

100 项与 ES-014 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	中国	科望（苏州）生物医药科技有限公司	2024-08-20
局部晚期恶性实体瘤	临床1期	中国	科望（苏州）生物医药科技有限公司	2023-02-21
转移性实体瘤	临床1期	中国	科望（苏州）生物医药科技有限公司	2023-02-21
实体瘤	临床1期	美国	科望（上海）生物医药科技有限公司初创企业	2022-05-09